Revolution Medicines Inc [RVMD] stock is trading at $48.24, up 1.31%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RVMD shares have gain 3.28% over the last week, with a monthly amount glided 4.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on September 05, 2025, and set its price target to $99. On August 19, 2025, Piper Sandler initiated with a Overweight rating and assigned a price target of $75 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $67 on August 15, 2025. Goldman initiated its recommendation with a Buy and recommended $65 as its price target on July 15, 2025. Needham reiterated a Buy rating for this stock on July 16, 2024, and upped its price target to $62. In a note dated July 12, 2024, Barclays initiated an Overweight rating and provided a target price of $52 on this stock.
Revolution Medicines Inc [RVMD] stock has fluctuated between $29.17 and $62.40 over the past year. Currently, Wall Street analysts expect the stock to reach $82 within the next 12 months. Revolution Medicines Inc [NASDAQ: RVMD] shares were valued at $48.24 at the most recent close of the market. An investor can expect a potential return of 69.98% based on the average RVMD price forecast.
Analyzing the RVMD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.42 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Revolution Medicines Inc’s Current Ratio is 11.79. In addition, the Quick Ratio stands at 11.79 and the Cash Ratio stands at 2.18.
Transactions by insiders
Recent insider trading involved Cislini Jeff, General Counsel, that happened on Sep 24 ’25 when 1799.0 shares were sold. Officer, JEFFREY TODD CISLINI completed a deal on Sep 24 ’25 to buy 1799.0 shares. Meanwhile, Chief Medical Officer Wei Lin sold 2160.0 shares on Sep 16 ’25.
